Sotera Health Announces Third-Quarter 2025 Earnings Release Date
CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC),…
IDI Announces Integration with TazWorks to Expand Access to IDIs Best-in-Class Identity Intelligence in the Background Screening Industry
October 21, 2025 12:21 ET | Source: Interactive Data, LLC BOCA RATON,…
Youxin Technology Ltd Regains Compliance with Nasdaq Listing Requirements
GUANGZHOU, CHINA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Youxin Technology Ltd (Nasdaq:…
Inveniam and Mantra unveil Inveniam Chain: A layer 2 blockchain for private real estate assets
ABU DHABI, United Arab Emirates and DUBAI, United Arab Emirates and NEW…
PIVOT-PO Phase 3 Data Show Tebipenem HBrs Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint…
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Long-term continuous OGSIVEO treatment for up to 4 years was associated with…
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Companys Ongoing Transformation
Intention follows comprehensive strategic review process and would represent the optimal capital…
IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
October 20, 2025 02:30 ET | Source: IO Biotech Cylembio plus pembrolizumab…
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha…
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”)…
